Citigroup says it's learned that Gilead's (GILD -1.7%) Phase 3 Neutrino study in Hepatitis C...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Citigroup says it's learned that Gilead's (GILD -1.7%) Phase 3 Neutrino study in Hepatitis C patients was fully enrolled in July after only one month of recruitment, which points to tremendous potential demand for the company's Hepatitis C treatment GS-7977. The firm reiterates a Buy with a $65 price target.